Efficacy and Safety Study to Compare Ibuprofen + Caffeine With Ibuprofen Alone in the Treatment of Headache

Mantercorp

Status and phase: Unknown; Phase 3

Conditions: Headache

Treatments: Drug: Ibuprofen; Drug: Ibuprofen plus caffeine

Study type: Interventional

Funder types: Industry

Identifiers

NCT01172405

IBU-CAF-01/09

Details and patient eligibility

About

Based on established therapeutic effect of ibuprofen in the treatment of headache attacks, and the action of caffeine in promoting better results when combined with treatments of first choice in the treatment of headache, this study is designed to:

• evaluate the efficacy of therapy with ibuprofen + caffeine in headache patients compared to ibuprofen alone;
• evaluate the tolerability of the association ibuprofen + caffeine compared to ibuprofen alone.

The hypothesis is that the association is superior to treatment with ibuprofen alone in terms of efficacy, while maintaining good tolerability.

Enrollment: 144 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with ability to read, understand and sign the IC;
• Patients with symptoms of frequent episodic tension headache, mild to moderate;
• Patients with symptoms of migraine with or without aura, of mild to moderate intensity;
• Patients who have had between two and five headache attacks in the last 30 days;
• Patients who accept the condition of ingesting less than three cups of coffee per day and / or reduce the intake of any beverage that contains caffeine;
• Patients who accept the condition not to drink any beverage that contains caffeine for 24 hours after drug administration.
• Patients able to understand and maintain the clinical protocol.
• Patients who started or changed prophylactic treatment for headache 30 days before inclusion.
• Female patients of childbearing age must agree to undergo pregnancy testing through urine.

Exclusion criteria

• Patients in whom headache began after 50 years of age;
• Patients with strong or disabling headaches;
• Patients with chronic daily headaches lasting up to 72 h or with cluster headaches not responsive to common analgesics;
• Patients with headaches occurring in 15 or more days per month;
• Patients with secondary headaches;
• Patients who overuse analgesics (acetylsalicylic acid up to 300 mg / day) or NSAIDs;
• Known hypersensitivity to components of both formulations of the drug test as the comparison;
• Known hepatic or renal diseases;
• Patients who are pregnant or intend to become pregnant or lactating;
• Patients with severe concomitant systemic diseases such as cancer, diabetes, congenital or acquired heart diseases, hematological diseases, convulsive disorders, autoimmune diseases, renal failure, severe infections, hormonal disorders, pulmonary disorders and peptic diseases;
• History of alcoholism or substance abuse.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

144 participants in 2 patient groups

Ibuprofen + Caffeine

Experimental group

Description:

72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.

Treatment:

Drug: Ibuprofen plus caffeine

Ibuprofen

Active Comparator group

Description:

72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.

Treatment:

Drug: Ibuprofen